Respiree announced today that it has incorporated in the US and will be incubating within Johnson & Johnson Innovation – JLABS @ South San Francisco from February 12, 2024. By expanding footprint within the US, Respiree aims to deepen its relationships and networks within the pharma and life science sector. Respiree was formerly a company at JLABS in Singapore.
Respiree announced today that it has become a resident of Johnson & Johnson Innovation – JLABS @ Shanghai (‘JLABS’) from February 21, 2023 , in order to expand its footprint with the goal of deepening its relationships and networks within the pharma and life science sector.
Digital therapeutics startup Respiree™ announces residency at JLABS @ Shanghai Read More
Digital therapeutics startup Respiree has received the United States Food and Drug Administration’s 510(k) clearance for its RS001 cardio-respiratory wearable.
It is part of the hospital’s smart remote health monitoring system project with A*STAR spinoff Respiree.
Changi General Hospital developing AI algorithms to predict patient deterioration Read More
The device could save up to 12 man-hours daily, allowing nurses to focus on other aspects of a patient’s well-being.
Changi General Hospital partners Respiree to advance patient care through smart remote monitoring of vital signs: Potential for wearable medical sensor to maximise and improve productivity gains
Respiree Pte Ltd made it through the first round and has been selected as a Finalist for Falling Walls Venture 2022
Falling Walls Finalist 2022 Read More
Digital health startup Respiree has raised S$4.7 million in Series Seed equity funding led by Oriza Greenwillow Technology Fund, SEEDS capital and high-net-worth investors that include the she1K angel syndicate.
Greenwillow Respiree Fund Raise Read More
Amidst this pandemic, Singapore continues to invest in science and innovation, as well as grow a strong pool of talented scientists – some of whom contribute to the fight against Covid-19 using AI analytics.
Dedicated to research and innovation for the public good, the Agency for Science, Technology and Research (A*STAR) interviews 2 of their scholars; Dr Sarah Luo, Principal Investigator at the Institute of Molecular and Cell Biology (IMCB), and Dr Gurpreet Singh, Senior Research Scientist at the Institute of Bioengineering and Bioimaging (IBB) and founder of Respiree Pte Ltd.
